To investigate serum APPs as predictive biomarkers for the immunotherapy response, levels of nine APPs (ACT, SAA, AGP, HP, AAT, CRP, A2M, CP and ALB) were measured in 139 patients with NSCLC prior to anti-PD-1 or anti-PD-L1 therapy (Table 1 and Table S1). The gene discussed is CP; the disease is non-small cell lung carcinoma.